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S296 Poster Session IIhomozygotes. The DFS of one year was 72.2% when the donors
have three or more aKIR, while if the donor had one or two
aKIR., the DFS of one year was 81.8%.
Conclusions: In HLA-identical sibling HSCT, the incidence of
aGVHD and severe aGVHD were higher in group of donor/recipi-
ent KIR completely identical.The differential expression of the num-
ber and subtype in aKIR may be related to the reduce occurrence of
disease relapse and better clinical outcome in HLA-identical sibling
HSCT.393
DAY +11 METHOTREXATE (MTX) MIGHT REDUCE THE RISK OF EN-
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EASE (GVHD) AFTER UNRELATED BONE MARROW TRANSPLANTATION
(U-BMT) WITH REDUCED-INTENSITY CONDITIONING REGIMENS
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The combination of calcineurin inhibitor and short MTX is often
used for GVHD prophylaxis after allogeneic stem cell transplanta-
tion. Although day +11 MTX is sometimes omitted due to severe
complications, the benefit of day +11MTX is controversial. To eval-
uate the role of day +11 MTX, we retrospectively reviewed the med-
ical records of 142 pts with various hematological malignancies who
underwent U-BMT between 2000 and 2007 with myeloablative
(MAC, n 5 96) or reduced-intensity conditioning (RIC, n 5 46)
regimens. Patient characteristics are shown in table 1.
Table 1. Patient Characteristics
Myeloablative Reduced-intensityDose of
MTX(MAC, n596) (RIC, n546)3 doses
(n514)4 doses
(n582)3 doses
(n512)4 doses
(n534)Age median
(range)34 (22-48) 39 (9-58) 57 (19-67) 56 (10-64)Disease AML 9 32 7 13
ALL 0 12 0 1
MDS 0 14 1 7
CML 1 11 0 2
ML 1 9 3 7
other 3 4 1 4Risk group High risk 11 57 10 22
Low risk 3 25 2 12HLA status identical 12 75 12 34
mismatched 2 7 0 0Calcineurin
inhibitorCyclosporine 5 38 7 24Tacrolimus 9 44 5 10MAC consisted of 12 Gy TBI-based (n5 50) or Bu (po 16 mg/kg or
iv 12.8 mg/kg, n5 46)-based regimen, and RIC consisted of Bu (po 8
mg/kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg) or Flu (180 mg/m2). GVHD prophylaxis consisted of cyclospor-
ine (starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml) or tacrolimus (starting dose 0.03 mg/kg/day civ, target whole
blood conc. 10-20 ng/ml) with short MTX scheduled on day +1, +3,
+6, and day +11 (10-7-7-7 mg/m2). No pts received ATG. Among
the 142 pts, planned day +11 MTX was omitted in 26 pts (MAC; n
5 14, RIC n5 12) due to various reasons including grade 3mucositis
(n5 21), febrile neutropenia (n5 12), grade 2 jaundice (n5 4), grade
2 mucositis (n 5 3), pneumonia (n 5 1), and sepsis (n 5 1). ES was
diagnosed when pts presented with $ 2 of the following symptoms
within 96 hrs of neutrophil engraftment: (1) fever (. 38C) without
an identifiable infectious reason, (2) skin rash (. 25% of BSA) not
because of drug reactions, (3) weight gain (. 2.5% of baseline
body weight), and (4) hypoxia (SPO2\ 94%), or pulmonary infil-
trates. The median follow-up in surviving pts was 1115 days (100-
3071). In both MAC and RIC groups, median day of neutrophilengraftment, OS, NRM and relapse rate at 2 yrs were not signifi-
cantly different between the 4-dose and 3-dose groups (MAC; day
+17 vs +16, 59% vs 48%, 23% vs 25%, and 26% vs 34%, RIC; day
+18.5 vs +16.5, 45% vs 58%, 43% vs 28%, and 20% vs 19%, respec-
tively). In the MAC group, there were no significant differences of
the incidences of ES and grade II to IV acute GVHD. In the RIC
group, however, the incidence of ES was significantly lower in the
4-dose group (26% vs 58%, p 5 0.02) and the incidence of grade
II to IV acute GVHD tended to be lower (48% vs 75%, p 5 0.07)
than in the 3-dose group. In conclusion, our study suggested that
day +11 MTX might reduce the risk of ES and acute GVHD.394
EVALUATION OF MYOCARDIAL AND HEPATIC T2* MRI CHANGES IN b-
THALASSEMIA MAJOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
RECIPIENTS AND THE EFFECT OF IRON OVERLOAD THERAPY
Hamidieh, A.A., Moeininia, F., Alimoghaddam, K., Jalili, M.,
Shamshiri, A., Ghavamzadeh, A. Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
Background: Iron deposition in the heart and liver are considered to
play a central role in the long term outcome of ex-thalassemic hem-
atopoetic stem cell transplantation (HSCT) survivors. There is a lack
of correlation between heart and liver iron load. Serum ferritin and
liver iron values have almost no predictive value for cardiac iron de-
position. This study was conducted in order to assess myocardial and
hepatic iron concentrations using T2* MRI and detection of any ef-
fect of transplantation itself and chelation therapy in ex-thalassemic
patients who survived beyond six months.
Methods: In this prospective, single-center study, during 14
months, 72 major thalassemia patients candidate for allogeneic
HSCTwere evaluated for iron overload by base line liver and cardiac
T2* MRI, liver biopsy and serum ferritin and subsequently 26 pa-
tients assessed again by T2*MRI and ferritin on 6th months after
successful HSCT. Finally deferoxamine was prescribed for 12 ex-
thalassemic patients at this time according to abnormal myocardial
or hepatic T2* values. T2* MRI and serum ferritin were performed
for these patients at the end of 6th months of chelation.
Results: At baseline, the cardiac T2* was normal (. 20 ms) in 46
(63.9%) of recipients, but 69 (82%) had hepatic siderosis. The liver
T2* (mean, 4.27 6 4.22 ms) was correlated significantly with serum
ferritin levels (r-0.8, p \ 0.001), but not with myocardial values
(mean, 25.3 6 10.5 ms). Although serum ferritin increased during
six months after HSCT (mean13516 941 to 5068 6 7674 ng/ml),
the myocardial and hepatic T2* measures were not changed signifi-
cantly. After about 6 months chelation therapy in 12 ex-thalassemic
patients the liver T2* improved (5.49 6 2.74 to 4.216 2.6 ms,
p0.008) with concomitant improvement in serum ferritin (mean
50686 7674 to 24506 1824 ng/ml), but differences in ferritin levels
were not significant. The cardiac T2* measures were not improved
during this time.
Conclusion: T2*MRI is an apropriate method for baseline evalua-
tion and monitoring of chelation therapy in b-thalassemia major
HSCT recipients, where as serum ferritin level may be confusing.395
IMPORTANCE OF CYCLOSPORINE LEVELS IN THE EARLY PERIOD AFTER
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Background: The importance of cyclosporine (CsA) levels to pre-
vent acute graft versus host disease (aGVHD) has been well docu-
mented after conventional conditioning allogeneic stem cell
transplatation (Allo-SCT), but its value in the reduced intensity con-
ditioning (RIC) setting has not been evaluated. The aim of the study
